CureVac Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 750

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.29B

  • Investors
  • 1

CureVac General Information

Description

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Contact Information

Website
www.curevac.com
Formerly Known As
CureVac AG
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Friedrich-Miescher-Strasse 15
  • 72076 Tubingen
  • Germany
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Friedrich-Miescher-Strasse 15
  • 72076 Tubingen
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CureVac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Merger/Acquisition 18-Dec-2025 $1.29B Completed Generating Revenue
17. 2PO 09-Feb-2023 Completed Generating Revenue
16. 2PO 29-Jan-2021 Completed Generating Revenue
15. PIPE 14-Aug-2020 Completed Generating Revenue
14. IPO 14-Aug-2020 Completed Generating Revenue
13. Later Stage VC 21-Jul-2020 Completed Generating Revenue
12. Debt - General 27-Jun-2020 Completed Generating Revenue
11. Grant 16-Mar-2020 Completed Generating Revenue
10. Later Stage VC 18-Oct-2017 $100M $1.04B Completed Clinical Trials - Phase 2
9. Later Stage VC 08-Nov-2016 $29.5M $935M Completed Clinical Trials - Phase 1
To view CureVac’s complete valuation and funding history, request access »

CureVac Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medi
Drug Discovery
Tubingen, Germany
750 As of 2026

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CureVac Competitors (36)

One of CureVac’s 36 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Moderna Formerly VC-backed Cambridge, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Novavax Corporation Gaithersburg, MD
BioCryst Pharmaceuticals Corporation Durham, NC
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
You’re viewing 5 of 36 competitors. Get the full list »

CureVac Patents

CureVac Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026234261-A1 Novel lipid nanoparticle formulations for delivery of nucleic acids, having a piperidine ring and two chains with two carboxyl groups each Pending 09-May-2025
WO-2026233566-A1 Optimized rna molecules Pending 09-May-2025
WO-2026234283-A1 Optimized rna molecules Pending 09-May-2025
WO-2025242815-A1 Immunotherapy of squamous cell carcinoma Pending 23-May-2024
GB-202404607-D0 Rna formulation Inactive 29-Mar-2024 A61K9/0019
To view CureVac’s complete patent history, request access »

CureVac Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CureVac Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Baden-Württemberg Government
Baillie Gifford Growth/Expansion Minority
Boehringer Ingelheim Corporation Minority
Chartwave Corporation Minority
Coppel Family Other Minority
You’re viewing 5 of 22 investors. Get the full list »

CureVac Acquisitions (1)

CureVac’s most recent deal was a Merger/Acquisition with Frame Therapeutics for . The deal was made on 08-Jun-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Frame Therapeutics 08-Jun-2022 Merger/Acquisition Drug Discovery
To view CureVac’s complete acquisitions history, request access »

CureVac ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.05 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view CureVac’s complete esg history, request access »

CureVac Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Curevac Belgium Ottignies-Louvain-La-Neuve, Belgium 2022
Frame Therapeutics Amsterdam, Netherlands 2018

CureVac FAQs

  • When was CureVac founded?

    CureVac was founded in 2000.

  • Where is CureVac headquartered?

    CureVac is headquartered in Tubingen, Germany.

  • What is the size of CureVac?

    CureVac has 750 total employees.

  • What industry is CureVac in?

    CureVac’s primary industry is Drug Discovery.

  • Is CureVac a private or public company?

    CureVac is a Private company.

  • What is the current valuation of CureVac?

    The current valuation of CureVac is .

  • What is CureVac’s current revenue?

    The current revenue for CureVac is .

  • How much funding has CureVac raised over time?

    CureVac has raised $2.78B.

  • Who are CureVac’s investors?

    Baden-Württemberg, Baillie Gifford, Boehringer Ingelheim, Chartwave, and Coppel Family are 5 of 22 investors who have invested in CureVac.

  • Who are CureVac’s competitors?

    Moderna, Sarepta Therapeutics, Novavax, BioCryst Pharmaceuticals, and Arcturus Therapeutics Holdings are some of the 36 competitors of CureVac.

  • When was CureVac acquired?

    CureVac was acquired on 18-Dec-2025.

  • Who acquired CureVac?

    CureVac was acquired by BioNTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process